Abstract: The disclosure is directed to novel solid-state forms of Compound 9 and pharmaceutically acceptable salts of Compound 9, compositions comprising the same, and methods of using the same, including use in treating cancer, hypoxia related pathologies, disorders leading to ischemia, and non-cancerous angiogenic diseases.

Abstract: Polymorphs of co-crystals of itanapraced and nicotinamide and pharmaceutical compositions and dosage forms containing the polymorphs are described. Methods of synthesizing the polymorphs and uses of polymorphs are also described.

Abstract: Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containing the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.

Abstract: Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containing the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.

Abstract: Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containing the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.

Abstract: Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containg the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.

Abstract: Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containing the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.

Abstract: Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containing the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.

Abstract: Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containing the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.

Abstract: The present disclosure is directed to a crystalline, hydrated form of afatinib dimaleate having about 2 to 3 molecules of water, designated as Form Z, a pharmaceutical composition comprising the form, its method of use for treating a patient, and process for its preparation.

Abstract: The present disclosure is directed to a crystalline, hydrated form of afatinib dimaleate having about 2 to 3 molecules of water, designated as Form Z, a pharmaceutical composition comprising the form, its method of use for treating a patient, and process for its preparation.

Abstract: An improved led fixture apparatus and manufacturing methods thereto is disclosed herein. In preferred embodiments, the apparatus comprises a power supply, a base, a circuit board mounted within the base, a LED connected to the circuit board, and wherein the base is constructed from material comprising forged metal and configured to act as a heat sync. In preferred embodiments, the base is made from forged aluminum alloy anodized for emissivity conduction and comprises a plurality of fins adapted to increase the surface area of the base to improve heat dissipation.

Abstract: A method for identifying new customers or recently changed telephone services is disclosed. The methodology discovers systems and methods for capturing telephone numbers that appear on the records of recent telephone calls of a communications network, which can or cannot be a network customer, and categorizing the telephone number as a known telephone number or an unknown telephone number. The methodology includes looking-up a name and address for telephone numbers, which are categorized as unknown telephone numbers, in a current directory service. A comparison can be performed using the looked-up name and address from the current directory service with names and addresses in a historical data source. If the looked-up name and address from the current directory service differ from name and address in the historical data source, the unknown telephone number is identified as a new customer or a recently changed telephone service.

Abstract: A disabling module in communication with a control module operates to disable or partially disable equipment in response to the failure of a user to complete a specific task, such as make a loan or lease payment. When a user makes a payment on an outstanding loan, usually a loan related to specific equipment, such as a motorized vehicle, a control module is notified of the payment. The control module causes the equipment to be enabled or disabled in accordance with payment receipt.

Abstract: A disabling module in communication with a control module operates to disable or partially disable equipment in response to the failure of a user to complete a specific task, such as make a loan or lease payment. When a user makes a payment on an outstanding loan, usually a loan related to specific equipment, such as a motorized vehicle, a control module is notified of the payment. The control module causes the equipment to be enabled or disabled in accordance with payment receipt.